Secukinumab (AIN-457) for the treatment of Psoriasis

被引：10

作者：

Jaleel, Tarannum ^{[1
]}

Elmets, Craig ^{[1
]}

Weinkle, Allison ^{[3
]}

Kassira, Sama ^{[2
]}

Elewski, Boni ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Dept Dermatol, EFH 414,1530 3rd Ave S, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA

[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 02期

关键词：

pharmacology; IL-17; Th; 17; AIN-457; psoriasis; secukinumab; SEVERE PLAQUE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; OPEN-LABEL; MULTIPLE-SCLEROSIS; TH17; CELLS; INFLIXIMAB INDUCTION;

D O I：

10.1586/17512433.2016.1129894

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.

引用

页码：187 / 202

页数：16

共 116 条

[1] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial [J].

Bachelez, Herve ;

van de Kerkhof, Peter C. M. ;

Strohal, Robert ;

Kubanov, Alexey ;

Valenzuela, Fernando ;

Lee, Joo-Heung ;

Yakusevich, Vladimir ;

Chimenti, Sergio ;

Papacharalambous, Jocelyne ;

Proulx, James ;

Gupta, Pankaj ;

Tan, Huaming ;

Tawadrous, Margaret ;

Valdez, Hernan ;

Wolk, Robert .

LANCET, 2015, 386 (9993) :552-561

[2] SECUKINUMAB REDUCES SACROILIAC JOINT AND SPINAL INFLAMMATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS: MRI DATA FROM A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (MEASURE 1) [J].

Baraliakos, X. ;

Braun, J. ;

Sieper, J. ;

Baeten, D. L. ;

Readie, A. ;

Ligozio, G. ;

Richards, H. .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 :281-281

[3] Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) [J].

Barker, J. ;

Hoffmann, M. ;

Wozel, G. ;

Ortonne, J. -P. ;

Zheng, H. ;

van Hoogstraten, H. ;

Reich, K. .

BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (05) :1109-1117

[4] Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) [J].

Blauvelt, A. ;

Prinz, J. C. ;

Gottlieb, A. B. ;

Kingo, K. ;

Sofen, H. ;

Ruer-Mulard, M. ;

Singh, V. ;

Pathan, R. ;

Papavassilis, C. ;

Cooper, S. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (02) :484-493

[5] Psoriasis [J].

Boehncke, Wolf-Henning ;

Schoen, Michael P. .

LANCET, 2015, 386 (9997) :983-994

[6] Burden of Disease: Psoriasis and Psoriatic Arthritis [J].

Boehncke, Wolf-Henning ;

Menter, Alan .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2013, 14 (05) :377-388

[7] Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study [J].

Chioato, A. ;

Noseda, E. ;

Stevens, M. ;

Gaitatzis, N. ;

Kleinschmidt, A. ;

Picaud, H. .

CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (10) :1597-1602

[8] IL-17 targeted therapies for psoriasis [J].

Chiricozzi, Andrea ;

Krueger, James G. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (08) :993-1005

[9] Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis [J].

Chiricozzi, Andrea ;

Guttman-Yassky, Emma ;

Suarez-Farinas, Mayte ;

Nograles, Kristine E. ;

Tian, Suyan ;

Cardinale, Irma ;

Chimenti, Sergio ;

Krueger, James G. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (03) :677-687

[10] Secukinumab failure in Crohn's disease: the yeast connection? [J].

Colombel, Jean Frederic ;

Sendid, Boualem ;

Jouault, Thierry ;

Poulain, Daniel .

GUT, 2013, 62 (05) :800-801

← 1 2 3 4 5 6 7 8 9 10 →